Interleukin-18 bioactivity and dose: data interpretation at a crossroads

Invest Ophthalmol Vis Sci. 2014 Dec 23;55(12):8349-50. doi: 10.1167/iovs.14-15786.

Authors

Sarah L Doyle¹, Peter Adamson², Francisco J López³, Peter Humphries⁴, Matthew Campbell⁴

Affiliations

¹ Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland;
² Ophthalmology, Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom;
³ Ophthalmology Discovery Performance Unit, GlaxoSmithKline, King of Prussia, Pennsylvania, United States; and.
⁴ Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland.

PMID: 25538010
DOI: 10.1167/iovs.14-15786

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Female
Humans
Interleukin-18 / metabolism*
Macular Degeneration / pathology*
Male
Retinal Pigment Epithelium / pathology*

Substances

Interleukin-18